Eisai Inc.
Global Headquarters:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
Woodcliff Lake
New Jersey
07677
United States
525 articles about Eisai Inc.
-
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD
10/16/2023
BioArctic AB's partner Eisai will present new data from the phase 3 Clarity AD study for its Alzheimer's disease treatment LEQEMBI® 100 mg/mL injection for intravenous use, as well as new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease conference.
-
Eisai to Present New Data From LEQEMBI® (lecanemab-irmb) Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
10/16/2023
Eisai Co. Ltd announced that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease treatment LEQEMBI® 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease conference.
-
Eisai to Present Research From Oncology Portfolio and Pipeline at ESMO Congress 2023
10/11/2023
Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.
-
Data from the Mayo Clinic shows limited eligibility for the anti-amyloid treatment. However, Michael Irizarry, Eisai’s deputy chief clinical officer, says some patients could still be eligible.
-
After a groundbreaking year in the Alzheimer’s space, Parkinson’s disease researchers express renewed hope based on a greater biological understanding of neurodegeneration.
-
Pivotal clinical trials in Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis are expected to read out this fall. Here's a closer look.
-
'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan
9/25/2023
BioArctic AB's partner Eisai announced that "LEQEMBI® Intravenous Infusion" has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease.
-
The losing streak continues for Merck and Eisai with their Keytruda-Lenvima combination failing to improve progression-free survival and overall survival in two late-stage lung cancer studies.
-
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
9/22/2023
Merck, known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer.
-
With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen’s Leqembi and Eli Lilly’s investigational donanemab.
-
In addition to massive revenues predicted for their developers, Leqembi—and possibly donanemab, if approved—should bring in substantial dollars to the healthcare industry.
-
While an initial analysis showed improvements in progression-free survival and objective response rate, a second analysis saw no improvement in overall survival.
-
With Eisai and Biogen’s Leqembi now fully approved, researchers are exploring combinations—including with therapies targeting tau and microglial function—that could increase its effectiveness.
-
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
7/19/2023
Eisai Co., Ltd. and Biogen Inc. announced that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb treatment showed reductions in amyloid-beta pathology and downstream biomarker changes.
-
Following the full approval of Leqembi, the CMS suggests expanding its coverage of beta-amyloid PET scans, which could improve the uptake of novel Alzheimer’s disease treatments.
-
Full data for Eli Lilly’s Phase III TRAILBLAZER-ALZ 2 study, presented Monday at the 2023 Alzheimer's Association International Conference, confirm positive results announced in May.
-
Recent data from the Phase III study of donanemab emphasize a correlation between amyloid and tau. Experts say a greater understanding of this link could further Alzheimer's drug development.
-
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research, Including Lecanemab and Anti-MTBR Tau Antibody E2814, at the Alzheimer's Association International Conference (AAIC) 2023
7/12/2023
Eisai Co. Ltd announced that the company will present the latest findings on its Alzheimer's disease pipeline and research, including Eisai's anti-amyloid beta protofibril* antibody for the treatment of Alzheimer's disease, lecanemab, and the company's investigational anti-MTBR** tau antibody, E2814, at the Alzheimer's Association International Conference.
-
Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) 2023
7/12/2023
BioArctic AB's partner Eisai will present the latest findings on lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzheimer's disease, at the Alzheimer's Association International Conference.
-
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
7/7/2023
Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application supporting the traditional approval of LEQEMBI® 100 mg/mL injection for intravenous use, making LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease.